Oncology

Exercise and healthy eating can have substantial impacts on reducing the risk of or managing serious chronic health conditions. However, in order to see the benefits of these health-protective behaviors, patients need to perform them consistently.

A phase 3 study, conducted by the Children’s Oncology Group among children and young adults between ages 1 and 30 diagnosed with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic leukemia, has found a 90% survival rate at 4 years posttreatment initiation—84% of these patients were declared cancer free at that point in their treatment trajectory. Results from this study will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, in Chicago, Illinois.

This week, the top managed care stories include Senator Bill Cassidy's new plan to lower healthcare costs; policy recommendations from the American Diabetes Association on how to lower insulin prices; and coverage from the American Society of Clinical Oncology annual meeting.

A new immunotherapy referred to as the "Toca regimen" is being investigated in a phase 2/3 randomized, multicenter, open-label trial.

Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.

A retrospective analysis conducted by researchers at the University of Louisville has found that less than 2% of the more than 7.5 million eligible smokers were screened for lung cancer in 2016 despite recommendations by the United States Preventive Services Task Force (USPSTF). These results will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, Chicago, Illinois.

Mortality rates have stabilized and incidence rates of late-stage disease have started to increase after 2 decades of decreasing rates. At the same time, rates of prostate-specific antigen screening have declined.

Rates of colon cancer are increasing in younger people, and as a result the American Cancer Society (ACS) is recommending that screening should start 5 years earlier, at 45 years of age rather than 50.

Use of the mobile and sensor technology, CYCORE—CYberinfrastructure for COmparative Effectiveness Research—to remotely monitor symptoms in patients with head and neck cancer (HNC) undergoing radiation therapy found CYCORE patients had lower symptoms overall and specific to HNC. These results are a part of the research to be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, Chicago, Illinois.

Pembrolizumab significantly improved overall survival (OS) and progression-free survival (PFS) as first-line treatment for squamous non–small cell lung cancer (NSCLC) in the pivotal phase 3 KEYNOTE-407 trial.

Immune cells that promote clotting within tumors in a specific type of lung cancer are actually assisting the tumor to spread throughout the body, according to a recent study published in Nature Communications.

During a press cast hosted by the American Society of Clinical Oncology ahead of the annual meeting, women with HER2-positive early-stage breast cancer who were treated with trastuzumab (Herceptin) for 6 months had a similar rate of disease-free survival as women who received the drug for 12 months, which is the current standard of care.

In general, practices and health systems don’t do a good job of integrating technology into practice, partly because most of the technology they use isn’t well suited to their needs, explained Charles Saunders, MD, CEO of Integra Connect.

Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research.

A new study analyzed the burden of multiple myeloma around the world, as well as access to effective treatments. From 1990 to 2016, incident cases and deaths from the disease have grown substantially.

Here is a preview of 5 of the biggest trial results to be presented at the American Society of Clinical Oncology (ASCO)'s Annual Meeting to be held on June 1 to 5, 2018, in Chicago, Illinois.

Technology can be used to make it easier for patients and practices to participate in clinical trials, while also easing some of the burden on research staff, said James Hamrick, MD, MPH, Kaiser Permanente and Flatiron Health.

Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.

While cancer incidence rates have decreased among men, they've remained stable among women and have increased among children; however, there has been an overall decline in mortality rates among men, women, and children.

Posters presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, highlighted healthcare costs for patients with treatment-resistant depression, off-label drug use in children with depressive disorder, and incidence of depression in patients diagnosed with late-stage cancer.

Rucaparib, the PARP inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).

Beyond helping with co-payment assistance for patients with cancer, CancerCare helps with practical and emotional supports for patients, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included President Donald Trump's plan to drive down drug prices; the FDA approved the first biosimilar of the year; a study found rapid uptake of PD-1 agents after FDA approval.